Introduction: Breast metastases are very uncommon, either from solid tumors or malignant melanoma.

Case Report: We present the case of a 42-year-old woman with a history of cutaneous melanoma of the shoulder excised 21 years ago. She presented with a palpable lump in the upper outer quadrant of the right breast. Ultrasound demonstrated a solid mass within a cystic lesion. A core biopsy was taken and first histology reported a poorly differentiated primary breast cancer suspected to be triple negative. MRI detected a satellite lesion in the same breast, a focus of suspected enhancement in the other breast, and the extramammary finding of an enhancing pulmonary lesion. Staging computed tomography detected widespread metastases to the lungs, brain, subcutaneous left shoulder, liver, pancreas, and hepatorenal recess. A core biopsy was taken from the left breast lesion and the previous slides were reviewed; histopathology and immunohistochemistry were in keeping with metastasis from melanoma.

Conclusions: The possibility of a metastatic lesion to the breast should be taken into account in any patient presenting with a breast lump and a previous history of melanoma. Breast involvement cannot be considered an isolated finding, as it might be the first manifestation of widespread disease.

Download full-text PDF

Source
http://dx.doi.org/10.5301/TJ.2015.14503DOI Listing

Publication Analysis

Top Keywords

breast
11
breast cancer
8
core biopsy
8
lesion breast
8
lesion
5
breast metastasis
4
metastasis cutaneous
4
cutaneous malignant
4
malignant melanoma
4
melanoma mimicking
4

Similar Publications

Ultrasound-responsive nanoparticles for nitric oxide release to inhibit the growth of breast cancer.

Cancer Cell Int

December 2024

Department of Ultrasound, Chongqing General Hospital, Chongqing University, Chongqing, 401147, China.

Gas therapy represents a promising strategy for cancer treatment, with nitric oxide (NO) therapy showing particular potential in tumor therapy. However, ensuring sufficient production of NO remains a significant challenge. Leveraging ultrasound-responsive nanoparticles to promote the release of NO is an emerging way to solve this challenge.

View Article and Find Full Text PDF

Background: Exclusive breastfeeding (EBF) is defined as feeding infants only breast milk of the mother or a wet nurse for the first six months, without additional food or liquids except the oral rehydration solution or drops/syrups of vitamins, minerals or medicines. The working status of women in developed countries adversely affects the EBF rates, which calls for an assessment in rapidly developing countries like India. Therefore, the primary aim of the present study is to determine the prevalence of EBF using the data from the National Family Health Surveys (NFHS 3, 4, 5) conducted between 2005 and 06, 2015-16 and 2019-21 to estimate the likelihood EBF according to mothers' employment status.

View Article and Find Full Text PDF

Targeting CDK2 to circumvent treatment resistance in HR breast cancer.

Trends Mol Med

December 2024

Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA. Electronic address:

Genetic and epigenetic defects of the p53 system have previously been associated with resistance to CDK4/6 inhibitors in women with HR breast cancer. Recent data from Kudo et al. demonstrate that CDK2-targeting agents may offer an effective strategy to circumvent such resistance by enforcing cellular senescence downstream of RBL2 dephosphorylation.

View Article and Find Full Text PDF

Dabrafenib upregulates hypoglycosylated MUC1 and improves the therapeutic efficacy of Tn-MUC1 CAR-T cells.

Sci Bull (Beijing)

December 2024

Breast Cancer Center, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China. Electronic address:

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!